Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination

Phase 1/2 Completed 41 enrolled University College, London GlaxoSmithKline · collab Medical Research Council · collab University of Oxford · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a clinical proof-of-concept (PoC) study of DNA vaccination after SAP depletion. The investigators will measure the immune responses to DNA vaccination against HIV-1 in healthy adult male volunteers, comparing a group in whom SAP has been completely depleted at the time of DNA vaccination and a control group vaccinated without SAP depletion.

Timeline

Start: 2013-10
Primary completion: 2016-02
Completion: 2016-09

Publications

Borthwick NJ, Lane T, Moyo N, Crook A, Shim JM, Baines I, Wee EG, Hawkins PN, Gillmore JD, Hanke T, Pepys MB. Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. PLoS One. 2018 May 17;13(5):e0197299. doi: 10.1371/journal.pone.0197299. eCollection 2018.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ChAdV63.HIVconsv	Vaccine	5e+10 vg	—
Subject	MVA.HIVconsv	Vaccine	2e+08 vg	—
Subject	miridesap	Small molecule	40 mg	Intravenous
Subject	pSG2.HIVconsv	Vaccine	4 mg	Intramuscular

Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination

Summary

Timeline

Publications

Drugs

Indications